ID   DAN-G
AC   CVCL_0243
SY   Dan-G; DanG; DANG; DAN
DR   CLO; CLO_0002698
DR   EFO; EFO_0006562
DR   MCCL; MCC:0000133
DR   CLDB; cl982
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 688
DR   BioSample; SAMN03472896
DR   BioSample; SAMN03473390
DR   BioSample; SAMN10987807
DR   cancercelllines; CVCL_0243
DR   Cell_Model_Passport; SIDM00950
DR   ChEMBL-Cells; CHEMBL3307281
DR   ChEMBL-Targets; CHEMBL614033
DR   CLS; 300162
DR   Cosmic; 1995382
DR   Cosmic; 2434109
DR   Cosmic-CLP; 1290797
DR   DepMap; ACH-000243
DR   DSMZ; ACC-249
DR   DSMZCellDive; ACC-249
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1290797
DR   GEO; GSM886971
DR   GEO; GSM888040
DR   GEO; GSM1669724
DR   IARC_TP53; 30030
DR   LiGeA; CCLE_849
DR   LINCS_LDP; LCL-1734
DR   PharmacoDB; DANG_281_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0243
DR   PubChem_Cell_line; CVCL_0243
DR   Wikidata; Q54828563
RX   CelloPub=CLPUB00416;
RX   PubMed=6231986;
RX   PubMed=11668190;
RX   PubMed=15126341;
RX   PubMed=15688027;
RX   PubMed=15770730;
RX   PubMed=22460905;
RX   PubMed=25167228;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26216984;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Population: Caucasian.
CC   Characteristics: Established from a xenograft produced by implantation of cells from the tumor of a patient with cancer of the pancreas in a nude mouse (CLS=300162).
CC   Doubling time: ~33 hours (DSMZ=ACC-249); 17.10 hours (GrayJW panel).
CC   HLA typing: A*02:01,02:01; B*07:02,13:02; C*06:02,06:02,07:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (CLS=300162; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.972_993+16del38; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.9%; Native American=1.77%; East Asian, North=3.79%; East Asian, South=0%; South Asian=0%; European, North=49.25%; European, South=44.28% (PubMed=30894373).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
ST   Source(s): CLS; Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D12S391: 17,20
ST   D13S317: 8 (CLS; Cosmic-CLP; PubMed=25877200)
ST   D13S317: 8,13 (DSMZ)
ST   D16S539: 8,11
ST   D18S51: 16
ST   D19S433: 13,14
ST   D1S1656: 12,17
ST   D21S11: 29,31.2
ST   D2S1338: 17,18
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D6S1043: 12
ST   D7S820: 10,13
ST   D8S1179: 10,11
ST   FGA: 20
ST   Penta D: 9,13
ST   Penta E: 7
ST   TH01: 9.3
ST   TPOX: 10
ST   vWA: 16,18
DI   NCIt; C8294; Pancreatic adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   CelloPub=CLPUB00416;
RA   Oberlin L.;
RT   "Treatment of pancreatic carcinoma cell lines in vitro and vivo with a
RT   monoclonal antibody against the transferrin receptor.";
RL   Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany.
//
RX   PubMed=6231986;
RA   Chu M.Y.W., Naguib F.N.M., Iltzsch M.H., el Kouni M.H., Chu S.-H.,
RA   Cha S., Calabresi P.;
RT   "Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by
RT   the uridine phosphorylase inhibitors benzylacyclouridine and
RT   benzyloxybenzylacyclouridine.";
RL   Cancer Res. 44:1852-1856(1984).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159;
RA   Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L.,
RA   Veltman J.A., van Kessel A.G., Hoglund M.;
RT   "Genome-wide array-based comparative genomic hybridization reveals
RT   multiple amplification targets and novel homozygous deletions in
RT   pancreatic carcinoma cell lines.";
RL   Cancer Res. 64:3052-3059(2004).
//
RX   PubMed=15688027; DOI=10.1038/sj.onc.1208383;
RA   Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H.,
RA   Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.;
RT   "Microarray analyses reveal strong influence of DNA copy number
RT   alterations on the transcriptional patterns in pancreatic cancer:
RT   implications for the interpretation of genomic amplifications.";
RL   Oncogene 24:1794-1801(2005).
//
RX   PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521;
RA   Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W.,
RA   Marten A.;
RT   "Synergistic effects of interferon-alpha in combination with
RT   chemoradiation on human pancreatic adenocarcinoma.";
RL   World J. Gastroenterol. 11:1521-1528(2005).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25167228; DOI=10.1038/bjc.2014.475;
RA   Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C.,
RA   Linnartz R., Zubel A., Slamon D.J., Finn R.S.;
RT   "KRAS mutational subtype and copy number predict in vitro response of
RT   human pancreatic cancer cell lines to MEK inhibition.";
RL   Br. J. Cancer 111:1788-1801(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//